免疫检查点抑制剂相关自身免疫性垂体炎的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (3): 403-406.

免疫检查点抑制剂相关自身免疫性垂体炎的研究进展

李佳忆, 幸兵^*

中国医学科学院北京协和医学院北京协和医院神经外科, 北京 100730

收稿日期:2019-06-02 修回日期:2019-09-30 出版日期:2020-03-05 发布日期:2020-03-02
通讯作者: ^*xingbingemail@aliyun.com

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis

LI Jia-yi, XING Bing^*

Department of Neurosurgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2019-06-02 Revised:2019-09-30 Online:2020-03-05 Published:2020-03-02
Contact: ^*xingbingemail@aliyun.com

摘要/Abstract

摘要： 免疫检查点抑制剂治疗恶性肿瘤过程中可诱发自身免疫性垂体炎(IH)。其发病率与药物种类有关。临床表现不特异,常合并垂体前叶功能减退,影像学检查可见垂体弥漫性增大。治疗主要是长期的激素替代治疗,不推荐大剂量糖皮质激素冲击治疗。

关键词: 免疫检查点抑制剂, 自身免疫性垂体炎, 免疫相关不良事件

Abstract: Immunotherapy induced hypophysitis (IH) has been demonstrated an autoimmune adverse effect of immune checkpoint inhibitors treatment of malignant tumors. The incidence of IH depends on types of immunotherapeutic agents. Patients with IH often present non-specific symptoms, ACTH, TSH and gonadotrophin deficiencies, and radiographic pituitary enlargement. Hormone replacement is recommended to be applied on IH patients. High-dose glucocorticoids but not supported by recent studies. This study systematically reviewed the prevalence, epidemiological characteristics, clinical characteristics, treatment and prognosis of IH.

Key words: immune checkpoint inhibitor, autoimmune hypophysitis, immune related adverse events

中图分类号:

R739.41

李佳忆, 幸兵. 免疫检查点抑制剂相关自身免疫性垂体炎的研究进展[J]. 基础医学与临床, 2020, 40(3): 403-406.

LI Jia-yi, XING Bing. Research progress of immune checkpoint inhibitor related autoimmune hypophysitis[J]. Basic & Clinical Medicine, 2020, 40(3): 403-406.

参考文献

[1]de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors[J]. Horm Metab Res, 2019, 51: 145-156.
[2]Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4: 173-182.
[3]Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J]. BMJ, 2018, 360: k793.doi:10.1136/bmj.k793.
[4]Guerrero E, Johnson DB, Bachelot A, et al. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis[J]. Eur J Cancer, 2019, 113: 10-13.
[5]Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights[J]. Pituitary, 2016, 19: 82-92.
[6]Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J]. J Clin Endocrinol Metab, 2014, 99: 4078-4085.
[7]Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series[J]. Am J Pathol, 2016, 186: 3225-3235.
[8]Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J]. Sci Transl Med, 2014, 6:230ra45.doi:10.1126/scitranslmed. 3008002.
[9]Bellastella G, Maiorino MI, Bizzarro A, et al. Revisita-tion of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects[J]. Pituitary, 2016, 19: 625-642.
[10]Lin CH, Chen KH, Chen KY, et al. Immune checkpoint inhibitor therapy-induced hypophysitis approximately a case series of Taiwanese patients[J]. J Formos Med Assoc, 2019, 118: 524-529.
[11]Iglesias P. Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach[J]. Eur J Intern Med, 2018, 47: 6-13.
[12]Brahmer JR, Lacchetti C, and Thompson JA. Manage-ment of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary[J]. J Oncol Pract, 2018, 14: 247-249.
[13]Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimu-mab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash[J]. J Natl Compr Canc Netw, 2014, 12: 1077-1081.
[14]Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT[J]. Acad Radiol, 2017, 24: 111-115.
[15]van der Hiel B, Blank CU, Haanen JB, et al. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab[J]. Clin Nucl Med, 2013, 38: e182-184.
[16]Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies[J]. Nat Rev Endocrinol, 2017, 13: 195-207.
[17]Joshi MN, Whitelaw BC, and Carroll PV. Mechanisms in endocrinology: hypophysitis: diagnosis and treatment[J]. Eur J Endocrinol, 2018, 179: R151-R163.
[18]Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma[J]. Eur J Endocrinol, 2015, 172: 195-204.
[19]Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors[J]. J Clin Endocrinol Metab, 2013, 98: 1361-1375.
[20]Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma[J]. Cancer, 2018, 124: 3706-3714.
[21]Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study[J]. Clin Cancer Res, 2015, 21: 749-755.